Zimmer Biomet Holdings, Inc. (ZBH): Daniel P Florin , Sr. VP, CFO of Zimmer Biomet Holdings, Inc. sold 15,000 shares on Jul 8, 2016. The Insider selling transaction was reported by the company on Jul 12, 2016 to the Securities and Exchange Commission. The shares were sold at $124.98 per share for a total value of $1,874,700.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 16, 2016, Tony W. Collins (VP, Controller and CAO) sold 3,611 shares at $116.43 per share price.On Jun 10, 2016, Daniel E. Williamson (Group President) sold 10,000 shares at $119.77 per share price.Also, On Jun 10, 2016, Stuart G. Kleopfer (President, Americas) sold 11,000 shares at $119.68 per share price.On Apr 18, 2016, Daniel P Florin (Sr. VP, CFO) sold 10,000 shares at $114.98 per share price.
Zimmer Biomet Holdings Inc: On Monday, Jul 11, 2016 heightened volatility was witnessed in Zimmer Biomet Holdings Inc which led to swings in the share price. The shares opened for trading at $124.79 and hit $125.49 on the upside , eventually ending the session at $125.08, with a gain of 0.15% or 0.19 points. The heightened volatility saw the trading volume jump to 12,20,278 shares. The 52-week high of the share price is $125.49 and the company has a market cap of $24,921 M . The 52-week low of the share price is at $88.27.
Company has been under the radar of several Street Analysts.Zimmer Biomet Holdings Inc is Initiated by Guggenheim to Neutral. The Rating was issued on Jun 9, 2016.Zimmer Biomet Holdings Inc is Reiterated by Barclays to Overweight and the brokerage firm has raised the Price Target to $ 135 from a previous price target of $130 .The Rating was issued on Apr 29, 2016.Zimmer Biomet Holdings Inc is Reiterated by RBC Capital Mkts to Outperform and the brokerage firm has raised the Price Target to $ 132 from a previous price target of $120 .The Rating was issued on Apr 15, 2016.
Zimmer Biomet Holdings Inc. formerly Zimmer Holdings Inc. is a musculoskeletal healthcare company. The Company designs manufactures and markets orthopedic reconstructive products; sports medicine biologics extremities and trauma products; spine bone healing craniomaxillofacial and thoracic products; dental implants and related surgical products. The Company manages its operations through three geographic segments: the Americas comprising principally of the United States and includes other North Central and South American markets; Europe comprising principally of Europe and includes the Middle East and African markets; and Asia Pacific comprising primarily of Japan and includes other Asian and Pacific markets. The Company markets and sells products through three channels: direct to healthcare institutions such as hospitals or direct channel accounts; through stocking distributors and healthcare dealers and directly to dental practices and dental laboratories.